Adaptilens, Inc., a pre-clinical company dedicated to transforming the standard of care for cataract surgery, today announced the closing of a Series A financing round of $17.5 million led by Perceptive Xontogeny Venture Funds (PXV Funds), with additional investments from Pillar VC, 380 Cap, and Accanto Partners. The capital will drive the development of the company’s Accommodating Intraocular Lens (A-IOL), the first and only biomimetic intraocular lens, through first-in-human trials.
Adaptilens, Inc. is an awardee of the MLSC’s Massachusetts Next Generation (MassNextGen) Initiative. This program supports underrepresented entrepreneurs with funding up to $100,000 per awardee and expand entrepreneurs’ network by providing year-round coaching sessions with serial entrepreneurs and subject matter experts